Host-versus-graft immune tolerance and disease correction following TLI/ATS/CTX compared with other conditioning before MHC-mismatched allogeneic BMT for β-thal. (A) Experimental design for comparison of nonmyeloablative TLI/ATS, ATS/CTX, and nonmyeloablative and myeloablative TBI/ATS/CTX conditioning in β-thal^+/− HW-80 recipients. BMT = 50 × 10⁶ bone marrow + 60 × 10⁶ spleen cells from WT BALB/c (H-2^d) donors. (B) Mean ± SEM donor chimerism (%) at D28 and D100 by FACS analysis of gated live lymphoid lineage (B220⁺, TCRαβ⁺) cells (top) and myeloid lineage (Gr-1/Ly6⁺, CD11b/Mac-1⁺) cells (bottom) in peripheral blood of β-thal^+/− HW-80 recipients of WT BALB/c BMT. Data are cumulative (n = 28 total experiments). N values are the number of recipients analyzed at D28 (first value) and D100 (second value), respectively, based upon cumulative survival of recipients at each time point. (C) Mean ± SEM peripheral blood hematocrit (%) at days 0 pre-BMT and 28 post-BMT in β-thal^+/− HW-80 recipients in panel B. N represents the total number of starting mice in each group at day 0. (D) Representative photomicrograph of Giemsa-stained β-thal^+/− HW-80 recipient peripheral blood film before BMT (left) and at D28 following TLI/ATS/CTX conditioning and BMT (middle) from its WT BALB/c donor (right).